Clinical trial · Interventional
Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation
Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation: a Prospective, Exploratory Study
NCT02044328CI-TRIAL-00056371ICAPEcompletedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Adjuvant therapy has been proved effective in treating earlier stage or less advanced non-small-cell lung cancer. This study is designed to evaluate the efficacy of icotinib as adjuvant therapy in treating stage IIA-IIIA adenocarcinoma patients with EGFR mutation. The primary endpoint is disease-free survival.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Icotinib | Drug | Icotinib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Icotinib
- description
- Patients receive icotinib 125 mg three times daily as adjuvant chemotherapy with for 18 months after surgery.
- interventionNames
- Drug: Icotinib
Primary outcomes (1)
- measure
- Disease-free survival
- timeFrame
- 2 years
Secondary outcomes (3)
- measure
- 1-year Survival Rates
- timeFrame
- 1 year
- measure
- 3-year Survival Rates
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * The patients present with operable stage IIA-IIIA (N0-1) lung adenocarcinoma with 19 or 21 exon mutation * The patients have no history of anti-cancer therapies including chemotherapy, radiation therapy * The patients' Eastern Cooperative Oncology Group scores are ≤ 0-1 * The patients signed the written informed consent Exclusion Criteria: * Patients with unresected tumor * Wild EGFR type * Allergic to the study drug * Patients have severe non-cancerous diseases * Patients are undergoing current administration of anti-cancer therapies, or are attending some other clinical trials
References
Publications (0)
Data not yet available
No reference posted for this study.